More articles from 13

  • Biomarker signatures for progressive idiopathic pulmonary fibrosis
    Britt Clynick, Tamera J. Corte, Helen E. Jo, Iain Stewart, Ian N. Glaspole, Christopher Grainge, Toby M. Maher, Vidya Navaratnam, Richard Hubbard, Peter M.A. Hopkins, Paul N. Reynolds, Sally Chapman, Christopher Zappala, Gregory J. Keir, Wendy A. Cooper, Annabelle M. Mahar, Samantha Ellis, Nicole S. Goh, Emma De Jong, Lilian Cha, Dino B.A. Tan, Lucy Leigh, Christopher Oldmeadow, E. Haydn Walters, R. Gisli Jenkins, Yuben Moodley
    European Respiratory Journal Mar 2022, 59 (3) 2101181; DOI: 10.1183/13993003.01181-2021
  • Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis
    Kevin R. Flaherty, Martin Kolb, Carlo Vancheri, Wenbo Tang, Craig S. Conoscenti, Luca Richeldi
    European Respiratory Journal Aug 2018, 52 (2) 1702593; DOI: 10.1183/13993003.02593-2017
  • Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension
    Athénaïs Boucly, Vincent Cottin, Hilario Nunes, Xavier Jaïs, Abdelatif Tazi, Grégoire Prévôt, Martine Reynaud-Gaubert, Claire Dromer, Catherine Viacroze, Delphine Horeau-Langlard, Christophe Pison, Emmanuel Bergot, Julie Traclet, Jason Weatherald, Gérald Simonneau, Dominique Valeyre, David Montani, Marc Humbert, Olivier Sitbon, Laurent Savale
    European Respiratory Journal Oct 2017, 50 (4) 1700465; DOI: 10.1183/13993003.00465-2017